1.Research Advances of Pan-negative Type of Non-small Cell Lung Cancer.
Li SUN ; Zhicheng XIONG ; Chengbo HAN
Chinese Journal of Lung Cancer 2018;21(2):129-138
In recent years, series of driver genes, such as EGFR, KRAS/NRAS, BRAF, PIK3CA, ALK and ROS1 and so on, have been found in non-small cell lung cancer (NSCLC) one after another with the development of molecular detecting technology. Targeted drugs bring benefits for these NSCLC patients with driver gene variations. However, some NSCLC did not have any known driver gene variations; we called it pan-negative lung cancer. In this paper, we summarize the concept, clinical pathological characteristics, the epidemiological characteristics, treatment and prognosis of pan-negative NSCLC.
Carcinoma, Non-Small-Cell Lung
;
diagnosis
;
drug therapy
;
genetics
;
pathology
;
Humans
;
Lung Neoplasms
;
diagnosis
;
drug therapy
;
genetics
;
pathology
;
Mutation
;
Prognosis
2.Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer.
Ting XIAO ; Jiali BAO ; Xiangning LIU ; Hui HUANG ; Honggang ZHOU
Chinese Journal of Lung Cancer 2022;25(10):756-763
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrous interstitial lung disease of unknown etiology. IPF is also considered to be among the independent risk factors for lung cancer, increasing the risk of lung cancer by 7% and 20%. The incidence of IPF complicated with lung cancer, especially non-small cell lung cancer (NSCLC), is increasing gradually, but there is no consensus on unified management and treatment. IPF and NSCLC have similar pathological features. Both appear in the surrounding area of the lung. In pathients with IPF complicated with NSCLC, NSCLC often develops from the honeycomb region of IPF, but the mechanism of NSCLC induced by IPF remains unclear. In addition, IPF and NSCLC have similar genetic, molecular and cellular processes and common signal transduction pathways. The universal signal pathways targeting IPF and NSCLC will become potential therapeutic drugs for IPF complicated with NSCLC. This article examines the main molecular mechanisms involved in IPF and NSCLC and the research progress of drugs under development targeting these signal pathways.
.
Humans
;
Carcinoma, Non-Small-Cell Lung/genetics*
;
Idiopathic Pulmonary Fibrosis/drug therapy*
;
Lung Neoplasms/genetics*
;
Lung/pathology*
;
Signal Transduction
3.Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer.
Chinese Journal of Lung Cancer 2018;21(8):635-640
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC.
.
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Drug Resistance, Neoplasm
;
genetics
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Molecular Targeted Therapy
;
methods
;
Mutation
;
Proto-Oncogene Proteins B-raf
;
genetics
4.Research Advances of Ang-2 in Non-small Cell Lung Cancer.
Chinese Journal of Lung Cancer 2018;21(11):868-874
Non-small cell lung cancer (NSCLC) is one of the malignant tumors with highest mortality in the world, it is still a difficult problem in clinical field. Its occurrence and development are closely associated with tumor angiogenesis. Angiopoietin-2 (Ang-2) is an important angiogenesis factor that has involved in many researches and it has been confirmed that the expression of Ang-2 is significantly up-regulated in tissues and blood of NSCLC. Meanwhile, Ang-2 is related to malignant biological behavior of cancer cells, making it a potential biological marker for the diagnosis and prognosis of NSCLC. At present, researches on Ang-2 how to promote the progression of NSCLC around the world are focused on Ang-2 regulating the proliferation, invasion, and metastasis of NSCLC. This paper summarized and estimated the studies and literature reports of regulatory mechanisms of Ang-2 in NSCLC, hopefully it could help looking for targeted drug treatment of Ang-2 in the future.
.
Angiopoietin-2
;
genetics
;
metabolism
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
Gene Expression Regulation, Neoplastic
;
drug effects
;
Humans
;
Lung Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
pathology
;
Molecular Targeted Therapy
;
Signal Transduction
;
drug effects
5.Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Chinese Journal of Lung Cancer 2018;21(2):110-115
Targeted therapy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) has been the standard modality as first-line treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). The third-generation EGFR-TKIs has been approved to overcome the EGFR T790M mutation in patients resistant to the first-or second-generation TKIs, which brings more survival benefits for patients with advanced NSCLC. Unfortunately, acquired resistance inevitably develops after application of approximately 10 months. Heterogeneities of the tumor determines the diversity of resistance. Mechanisms of resistance to the third-generation TKIs includs EGFR-dependent pathway (such as new EGFR mutations, T790M reduction/disappearance and EGFR amplification, etc.) and EGFR-independent pathway (such as bypass pathway activation and histological transformation, etc.). In this paper, we reviewed principle mechanisms of acquired resistance to third-generation EGFR-TKIs.
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
genetics
;
pathology
;
Drug Resistance, Neoplasm
;
drug effects
;
ErbB Receptors
;
antagonists & inhibitors
;
genetics
;
metabolism
;
Humans
;
Lung Neoplasms
;
drug therapy
;
genetics
;
pathology
;
Protein Kinase Inhibitors
;
pharmacology
;
therapeutic use
;
Signal Transduction
;
drug effects
6.The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells.
Ji Youn HAN ; Yeun Jun CHUNG ; Sung Won PARK ; Jung Soo KIM ; Mun Gan RHYU ; Hoon Kyo KIM ; Kyung Shick LEE
The Korean Journal of Internal Medicine 1999;14(1):42-52
OBJECTIVES: Given the roles of bcl-2, bax and p53 in apoptosis, we investigated the effect of their expression on the response to cisplatin in order to understand the molecular events of cisplatin-resistance in lung cancers. METHODS: Three parental human lung cancer cell lines (PC9, PC14 and H69) and their in vitro selected cisplatin-resistant sublines were examined. Cells treated with cisplatin were processed for acridine orange and ethidium bromide staining and DNA gel electrophoresis for the morphologic detection of apoptosis. The endogenous levels of bcl-2, bax and p53 protein expression in lung cancer cells were assessed by Western blot analysis and DNA of polymerase chain reaction-amplified exon 5 to 8 of p53 gene was directly sequenced. RESULTS: H69, which had bcl-2 expression, p53 mutation and decreased expression of p53 and bax, was relatively resistant to cisplatin and delayed and reduced apoptosis. Although apoptosis was markedly reduced in cisplatin-resistant sublines compared to their parental cells, there were no significant differences in the expression of p53, bcl-2 and bax. CONCLUSIONS: Cisplatin-resistance was associated with the reduced cellular susceptibility to apoptosis. Cancer cells with the natural expression of bcl-2 and p53 mutation may be more resistant to cisplatin and less susceptible to apoptosis.
Antineoplastic Agents/pharmacology*
;
Apoptosis/genetics
;
Apoptosis/drug effects*
;
Cisplatin/pharmacology*
;
Drug Resistance
;
Gene Expression
;
Genes, bcl-2
;
Genes, p53
;
Human
;
Lung Neoplasms/pathology
;
Lung Neoplasms/genetics
;
Lung Neoplasms/drug therapy
;
Proto-Oncogene Proteins/genetics
;
Tumor Cells, Cultured
7.Disparities of EGFR mutations between Biopsy and Rebiopsy in Non-small Cell Lung Cancer Patients.
Hui LI ; Shi YAN ; Xianhong LIU ; Ying LIU ; Lixia MA ; Ying WANG ; Yan LIU ; Ying CHENG
Chinese Journal of Lung Cancer 2018;21(11):821-827
BACKGROUND:
Epidermal growth factor receptor (EGFR)-based targeted therapy improves the survival of patients with advanced lung adenocarcinoma harboring EGFR mutations. However, factors including treatment or heterogeneity partly contribute to EGFR genetic status alteration between baseline and disease progresses (PD). The aim of this study is to compare difference of EGFR mutations between biopsy and rebiopsy in real world.
METHODS:
Data from 61 paired specimens performed EGFR testing in Jilin Provincial Cancer Hospital between January 2015 and December 2017 were collected and analyzed. The specimens were collected at baseline and PD, confirmed by histology or cytology and categorized as tumor tissue, malignant pleural effusion or plasma. All patients were naive and received chemotherapy or targeted therapy as first-line treatment. Amplification Refractory Mutation System (ARMS) was used to detect EGFR mutations.
RESULTS:
EGFR mutation rate in tumor tissue, pleural effusion or blood was 90.2% vs 88.5%, 6.6% vs 6.6% and 3.2% vs 4.9% at baseline or PD respectively and discrepancy was 72% and 36.3% for the same (n=50) or different (n=11) type of specimens. The EGFR mutation rate was 95.1% and 91.8% in patients before and after treatment, and the discrepancy was 63.9%, among which, 69.2% and 92.3% in chemotherapy-treated patients (n=13) with discrepancy to 46.1% (6/13), and 100.0% and 91.7% in EGFR-TKI-treated patients (n=48) with discrepancy to 70.8%. There were four types of alterations in terms of EGFR mutations: wild type turned into mutation (4.9%), mutation disappeared (8.2%), sensitive mutations transformed (1.6%), and new mutations appeared (49.1%).
CONCLUSIONS
In real world, the EGFR mutation status in advanced non-small cell lung cancer (NSCLC) patients altered significantly, due to tissue resources and therapeutic approaches, implying the importance of rebiopsy and real-time detection of EGFR mutation, in order to provide data to guide precise strategy in the following treatment.
Adult
;
Aged
;
Biopsy
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
ErbB Receptors
;
antagonists & inhibitors
;
genetics
;
Female
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Male
;
Middle Aged
;
Mutation
;
Protein Kinase Inhibitors
;
therapeutic use
;
Retrospective Studies
;
Treatment Outcome
8.A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib.
Yudong SU ; Zhaoting MENG ; Xiaoyan XU ; XinYue WANG ; Ran ZUO ; Yunxia HOU ; Kai LI ; Peng CHEN
Chinese Journal of Lung Cancer 2018;21(5):428-430
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib.
.
Adenocarcinoma
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Adenocarcinoma of Lung
;
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Humans
;
Indoles
;
therapeutic use
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
pathology
;
Male
;
Mutation
;
Proto-Oncogene Proteins p21(ras)
;
genetics
;
metabolism
;
Quinolines
;
therapeutic use
9.EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer.
Yu HAN ; Jian-ming XU ; Hai-qing DUAN ; San-tai SONG ; Xiao-qing LIU ; Yang ZHANG ; Jing-sheng ZHANG
Chinese Journal of Oncology 2007;29(4):278-283
OBJECTIVETo investigate the correlation between mutation in EGFR tyrosine kinase domain and tumor response as well as prognosis in advanced stage non-small cell lung cancer (NSCLC) treated with iressa.
METHODSFrom May 2002 to Feb. 2005, iressa was orally administered at a dose of 250 mg once daily for 106 advanced stage NSCLC patients until occurrence of disease progression or intolerable toxicity. Cancer tissue was obtained from these patients, and DNA was extracted for analysis of mutation in exon 18 to 24 of EGFR. Exon 18 to 24 of EGFR were amplified by nest PCR, sequenced and analyzed from both sense and antisence directions.
RESULTSPrimary NSCLC tissue specimens consisted of 25 frozen tissue blocks and 81 paraffin-embedded tumor tissue blocks from 106 consecutive NSCLC patients. Mutation was found to be more frequent in the adenocarcinoma than in the squamous cell carcinoma (35.9% vs 14.3%, P =0.033). Mutation was identified in 32 patients (30.2%). Response rate to iressa was 71.9% in the patients with EGFR mutation versus 13.5% in those without mutation (P <0.01). Compared with the patients without EGFR mutation, those with mutation had longer overall survival (median, 13.45 vs. 5.25 months; P<0.01) and median time to progression (median, 8.35 vs. 3.0 months; P <0.01).
CONCLUSIONEGFR mutation may be positively correlated with the response and survival in advanced stage Chinese NSCLC patient treated with iressa.
Adenocarcinoma ; drug therapy ; genetics ; pathology ; Adolescent ; Adult ; Aged ; Antineoplastic Agents ; therapeutic use ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; genetics ; pathology ; Carcinoma, Squamous Cell ; drug therapy ; genetics ; pathology ; Exons ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms ; drug therapy ; genetics ; pathology ; Male ; Middle Aged ; Neoplasm Staging ; Point Mutation ; Prognosis ; Quinazolines ; therapeutic use ; Receptor, Epidermal Growth Factor ; genetics ; Sequence Deletion
10.Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation Treated with Ensartinib: A Case Report and Literature Review.
Donglai LV ; Chunwei XU ; Chong WANG ; Qiuju SANG
Chinese Journal of Lung Cancer 2023;26(1):78-82
Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 2%-5% of all NSCLC cases, and is almost exclusively detected in patients with lung adenocarcinoma. Thus, ALK testing is not routinely performed in the LSCC population, and the efficacy of such treatment for ALK-rearranged LSCC remains unknown. Echinoderm microtubule associated protein like 4 (EML4)-ALK (V1) and TP53 co-mutations were identified by next generation sequencing (NGS) in this patient with advanced LSCC. On December 3, 2020, Ensatinib was taken orally and the efficacy was evaluated as partial response (PR). The progression-free survival (PFS) was 19 months. When the disease progressed, the medication was changed to Loratinib. To our knowledge, Enshatinib created the longest PFS of ALK-mutant LSCC patients treated with targeted therapy since literature review. Herein, we described one case treated by Enshatinib involving a patient with both EML4-ALK and TP53 positive LSCC, and the relevant literatures were reviewed for discussing the treatment of this rare disease.
.
Humans
;
Carcinoma, Non-Small-Cell Lung/drug therapy*
;
Lung Neoplasms/pathology*
;
Anaplastic Lymphoma Kinase/metabolism*
;
Carcinoma, Squamous Cell/genetics*
;
Mutation
;
Cytoskeletal Proteins/genetics*
;
Lung/pathology*
;
Oncogene Proteins, Fusion/genetics*
;
Protein Kinase Inhibitors/therapeutic use*
;
Tumor Suppressor Protein p53/genetics*